



(51) International Patent Classification:

A61K 9/14 (2006.01) A61P 11/00 (2006.01)
A61K 31/167 (2006.01) A61P 11/06 (2006.01)
A61K 31/57 (2006.01)

(21) International Application Number:

PCT/EP2013/051187

(22) International Filing Date:

23 January 2013 (23.01.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12152392.2 25 January 2012 (25.01.2012) EP

(71) Applicant: **CHIESI FARMACEUTICI S.P.A.** [IT/IT];
Via Palermo, 26/A, I-43100 Parma (IT).

(72) Inventors: **MONARI, Elisa**; Chiesi Farmaceutici S.p.A.,
Via Palermo, 26/A, I-43100 Parma (IT). **CANTARELLI,**
Anna Maria; Chiesi Farmaceutici S.p.A., Via Palermo,
26/A, I-43100 Parma (IT). **COCCONI, Daniela**; Chiesi
Farmaceutici S.p.A., Via Palermo, 26/A, I-43100 Parma
(IT). **PASQUALI, Irene**; Chiesi Farmaceutici S.p.A., Via
Palermo, 26/A, I-43100 Parma (IT).

(74) Agent: **MINOJA, Fabrizio**; Bianchetti Bracco Minoja
S.R.L., Via Plinio, 63, I-20129 Milano (IT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: DRY POWDER FORMULATION COMPRISING A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATION

(57) Abstract: The invention relates to a dry powder formulation comprising corticosteroid and a beta₂-adrenergic drug in combination, its process preparation, and therapeutic uses thereof.



WO 2013/110632 A1